Clinical Trial Update: Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC [Phase 3]

View source ↗

Summary

Phase 3 switch study evaluating switching to emtricitabine/tenofovir alafenamide in HIV-1-infected adults virologically suppressed on ABC/3TC-containing regimen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Emtricitabine/Tenofovir Alafenamide (emtricitabine/tenofovir alafenamide)

Snippet

Sponsor: Gilead Sciences | Conditions: HIV-1 Infection | Phase 3 | Status: COMPLETED | Results posted: 2018-06-11